2-((4-oxo-3,5-dibromo-2,5-cyclohexadien-1-ylidene)(4-hydroxy-3,5-dibromophenyl)methyl)-3,4,5,6-tetrabromophenyl-sulphonic acid sodium salt

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((4-oxo-3,5-dibromo-2,5-cyclohexadien-1-ylidene)(4-hydroxy-3,5-dibromophenyl)methyl)-3,4,5,6-tetrabromophenyl-sulphonic acid sodium salt
• 英文别名: 2-((4-oxo-3,5-dibromo-2,5-cyclohexadien-1-ylidene)(4-hydroxy-3,5-dibromophenyl)methyl)-3,4,5,6-tetrabromophenylsulfonic acid sodium salt；Sodium;2,6-dibromo-4-[(3,5-dibromo-4-oxocyclohexa-2,5-dien-1-ylidene)-(2,3,4,5-tetrabromo-6-sulfophenyl)methyl]phenolate；sodium;2,6-dibromo-4-[(3,5-dibromo-4-oxocyclohexa-2,5-dien-1-ylidene)-(2,3,4,5-tetrabromo-6-sulfophenyl)methyl]phenolate
• 化学式: C₁₉H₅Br₈O₅S*Na
• 分子量: 1007.53
• InChiKey: GFMOPDHPAXHAQX-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  5.82
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((4-oxo-3,5-dibromo-2,5-cyclohexadien-1-ylidene)(4-hydroxy-3,5-dibromophenyl)methyl)-3,4,5,6-tetrabromophenyl-sulphonic acid sodium salt 在 溶剂黄146 作用下， 以 水 为溶剂， 以94.5 %的产率得到四溴酚蓝
  参考文献：
  名称：

  CN116425714

  摘要：

  公开号：
• 作为产物：
  描述：

  四溴酚蓝 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 以88.5 g的产率得到2-((4-oxo-3,5-dibromo-2,5-cyclohexadien-1-ylidene)(4-hydroxy-3,5-dibromophenyl)methyl)-3,4,5,6-tetrabromophenyl-sulphonic acid sodium salt
  参考文献：
  名称：

  CN116425714

  摘要：

  公开号：

文献信息

• [EN] DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DE LA DIFFERENCIATION ET UTILISATIONS ASSOCIEES
  申请人：UNIV QUEENSLAND

  公开号：WO2005065686A1

  公开（公告）日：2005-07-21

  This invention discloses methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signalling pathway, especially the FGF-1 or FGF-2 signalling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma and lipomatosis.

  该发明揭示了调节前脂肪细胞分化潜能和/或增殖的方法和药剂。更具体地，本发明揭示了调节成纤维细胞生长因子（FGF）信号通路的方法和药剂，特别是FGF-1或FGF-2信号通路，用于治疗或预防与脂肪相关的疾病，包括但不限于肥胖、脂肪瘤和脂肪增生。
• Differentiation modulating agents and uses therefor
  申请人：Prins Bernhard Johannes

  公开号：US20050282733A1

  公开（公告）日：2005-12-22

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR
  申请人：Prins Johannes Bernhard

  公开号：US20120059047A1

  公开（公告）日：2012-03-08

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• [EN] ARYL AND HETEROARYL COMPOUNDS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS<br/>[FR] COMPOSES ARYLES ET HETEROARYLES UTILES COMME ANTAGONISTES DU FACTEUR DE CROISSANCE DES FIBROBLASTES (FGF)
  申请人：EISAI CO LTD

  公开号：WO2000030632A1

  公开（公告）日：2000-06-02

  Aryl and heteroaryl compounds, pharmaceutical compositions containing the compounds, and methods for using the pharmaceutical compositions for modulating the activity of the FGF family of peptides are provided. Methods for inhibiting the binding of an FGF peptide to an FGF receptor by contacting the receptor with the aromatic acid are also provided. Methods for treating FGF-mediated disorders by administering effective amounts of one or more of these compounds or pharmaceutically acceptable derivatives thereof that inhibit the activity of one or more FGF peptides are also provided.
• CN116425714
  申请人：——

  公开号：——

  公开（公告）日：——